View Exam | PowerPak

1. Which of the following was an update to the Centers for Disease Control and Prevention (CDC) 2021 HIV PrEP clinical practice guideline?

A. Addition of persons who inject drugs as candidates for PrEP. B. Addition of a recommendation to inform all sexually active adults and adolescents about PrEP. C. Offering the 2:1:1 intermittent PrEP regimen as an option for all at-risk patients. D. Adding a requirement that creatinine clearance be obtained every 3 months for all patients on PrEP.

2. Which statement regarding PrEP is true?

A. Daily PrEP with tenofovir alafenamide (TAF)/emtricitabine (FTC) is approved for heterosexual women and transgender men but not for transgender women. B. On-demand (2:1:1) oral PrEP with tenofovir disoproxil fumarate (TDF)/FTC is guideline-recommended for all patients. C. Based on clinical trials, long-acting injectable cabotegravir (CAB-LA) and oral TDF/FTC provide the same level of protection against HIV infection when used as PrEP. D. If using CAB-LA for PrEP, HIV testing with an HIV-1 RNA test is recommended at initiation and then at follow-up visits.

3. Which of the following antiretroviral therapy single-tablet regimens (STR) should not be used for a patient with HIV who is on hemodialysis?

A. Bictegravir/tenofovir alafenamide/emtricitabine B. Elvitegravir/cobicistat/tenofovir alafenamide/emtricitabine C. Dolutegravir/lamivudine D. Dolutegravir/rilpivirine

4. The most important intervention to help a patient with HIV adhere to therapy is to:

A. Give them 3 more months on their current approach and encourage them to do better. B. Switch to a different therapy because they are failing their current regimen. C. Discuss with the patient their individual needs and pair them with the best available regimen. D. Ask the patient to read materials on their illness so they learn how to take their medications appropriately.

5. In clinical trials with cabotegravir (CAB) + rilpivirine (RPV) extended-release injectable suspension, approximately what percentage of patients preferred injectable therapy to oral?

A. 55% B. 75% C. 87% D. 97%

6. Your patient — a 49-year-old man with HIV, diabetes mellitus, hypertension, moderate renal insufficiency, chronic hepatitis B, and obesity — is seen for follow-up. His HIV history is notable for previously having advanced HIV disease when he was first diagnosed 4 years ago, which was complicated by Pneumocystis pneumonia and oral and esophageal candidiasis. At that time, his CD4 cell count was 10 cells/mm³ and his HIV viral load was 720,000 copies/mL. However, he has been stable for the past several years and currently is receiving tenofovir alafenamide/emtricitabine/bictegravir. His most recent CD4 cell count was 380 cells/mm³, with a viral load <20 copies/mL. If you consider switching his regimen to dolutegravir/lamivudine, which of the following findings would be an absolute contraindication to making this change?

A. A CD4 cell count nadir of 10 cells/mm³ B. HIV viral load <500,000 copies/mL at screening C. Chronic hepatitis B D. Creatinine clearance <50 mL/min

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following was an update to the Centers for Disease Control and Prevention (CDC) 2021 HIV PrEP clinical practice guideline?

2. Which statement regarding PrEP is true?

3. Which of the following antiretroviral therapy single-tablet regimens (STR) should not be used for a patient with HIV who is on hemodialysis?

4. The most important intervention to help a patient with HIV adhere to therapy is to:

5. In clinical trials with cabotegravir (CAB) + rilpivirine (RPV) extended-release injectable suspension, approximately what percentage of patients preferred injectable therapy to oral?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following was an update to the Centers for Disease Control and Prevention (CDC) 2021 HIV PrEP clinical practice guideline?

2. Which statement regarding PrEP is true?

3. Which of the following antiretroviral therapy single-tablet regimens (STR) should not be used for a patient with HIV who is on hemodialysis?

4. The most important intervention to help a patient with HIV adhere to therapy is to:

5. In clinical trials with cabotegravir (CAB) + rilpivirine (RPV) extended-release injectable suspension, approximately what percentage of patients preferred injectable therapy to oral?

« Return to Activity

Customers who Purchased
this Activity also Purchased